Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 31;16(10):e72784.
doi: 10.7759/cureus.72784. eCollection 2024 Oct.

Magnetic Resonance Imaging Features for Distinguishing High-Grade From Low-Grade Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis

Affiliations
Review

Magnetic Resonance Imaging Features for Distinguishing High-Grade From Low-Grade Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis

Wilhelmina N Hauwanga et al. Cureus. .

Abstract

Soft tissue sarcomas are malignant tumors characterized by heterogeneity and are associated with a high mortality rate. Histopathological grading is considered a pivotal factor in prognostication and treatment planning. While core needle biopsy exhibits high accuracy in determining tumor histology, it fails in some cases, potentially misclassifying high-grade tumors as low-grade. Magnetic resonance imaging (MRI) has been evaluated as an adjunctive tool for predicting histopathological tumor grade. This systematic review and meta-analysis evaluated MRI features capable of distinguishing high-grade from low-grade tumors in patients with soft tissue sarcoma. A literature search was carried out in PubMed, Embase, and Cochrane Central in May 2024. The following features were evaluated for both low-grade and high-grade tumors: tumor size, heterogeneity on T2, presence of necrotic areas, margin definition on T1, and post-contrast peritumoral enhancement. Statistical analysis was conducted using the OpenMeta[Analyst] software (Providence, RI: Brown University), applying random effects models for pooled analyses with a 95% confidence interval (CI) based on the inverse variance method. A total of four studies, involving 343 patients categorized by tumor grade (high-grade or low-grade), who underwent MRI, were included in the analysis. The meta-analysis found similar incidences of tumor sizes less than 5 cm in both high-grade and low-grade tumors (22.7%; 95% CI: 10.3-25% vs. 27%; 95% CI: 2.7-51.2%) and tumor sizes greater than 5 cm (71.3%; 95% CI: 64-78.6% vs. 52%; 95% CI: 23.6-80.5%). High-grade tumors showed a higher incidence of post-contrast peritumoral enhancement compared to low-grade tumors (66%; 95% CI: 43-89% vs. 26%; 95% CI: 4.6-47.4%) as well as heterogeneity on T2 greater than 50% (72.4%; 95% CI: 49.3-95.4% vs. 25.4%; 95% CI: 5.2-56%). Additionally, high-grade tumors had a lower incidence of the absence of necrotic signal compared to low-grade tumors (28.8%; 95% CI: 8.5-49.1% vs. 68%; 95% CI: 57.5-78.6%). Our findings suggest that post-contrast peritumoral enhancement, presence of necrotic areas, and heterogeneity on T2 greater than 50% are MRI features associated with high-grade tumors in soft tissue sarcoma. Tumor size, however, does not appear to be a reliable indicator for differentiating tumor grade.

Keywords: heterogeneity; magnetic resonance imaging (mri); necrotic signal; peritumoral enhancement; soft tissue sarcoma; tumor grade.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram

References

    1. Soft tissue sarcomas in adolescents and young adults. Weiss AR, Harrison DJ. J Clin Oncol. 2024;42:675–685. - PubMed
    1. SEER Cancer Statistics Review (CSR) 1975-2014. Howlader N, Noone A-M, Krapcho M, et al. https://seer.cancer.gov/archive/csr/1975_2014/ National Cancer Institute. Bethesda, MD. 2018;21:12.
    1. Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Bauer HC, Trovik CS, Alvegård TA, et al. Acta Orthop Scand. 2001;72:150–159. - PubMed
    1. Rhabdomyosarcoma. Dasgupta R, Fuchs J, Rodeberg D. Semin Pediatr Surg. 2016;25:276–283. - PubMed
    1. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Brennan MF, Antonescu CR, Moraco N, Singer S. Ann Surg. 2014;260:416–421. - PMC - PubMed

LinkOut - more resources